RTI Surgical, a CDMO in regenerative medicine, has entered into an agreement to acquire Collagen Solutions, a global supplier of engineered medical-grade collagen and xenograft tissue with applications in cardiac, sports medicine and orthopedics.
 
The acquisition expands RTI’s portfolio of allograft and xenograft biomaterials at scale and follows the company’s acquisition of Cook Biotech earlier in the year. RTI’s product portfolio enables the company to partner with customers and surgeons to develop innovative solutions focused on improving patient outcomes.
 
Collagen Solutions is headquartered in Eden Prairie, Minneapolis, with additional strategically located sites in the UK and New Zealand.
 
Olivier Visa, President and Chief Executive Officer, RTI Surgical, said: “Collagen Solutions is an excellent strategic fit for RTI Surgical, bringing specialized and complementary capabilities and expertise in soft tissue engineering. Together, we are building on a significant track record with a combined 50 years of experience in developing products to help millions of patients in regenerative medicine. We are thrilled to welcome the talented Collagen team to RTI Surgical, and to expand our partnerships with customers to improve patient healing, accelerate recovery and help prevent complications.”
 
Rick Mulford, CEO of Collagen Solutions, said, “RTI Surgical shares our strong commitment to quality, innovation and customer care, making it the ideal new owner for Collagen Solutions. As we transition, I’m confident RTI will continue to drive the development of collagen-based biomaterials and effectively expand its work in cardiac and other clinical areas. We’re excited for the future of Collagen Solutions under RTI’s leadership.”